Physician profile
Anand Saranathan
NPI 1760652119
$108,950.71
in general payments reported to CMS, 2019-2025
46 companies · $6,964 in 2025
The $6,964 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,418 · 2021: $9,621 · 2022: $34K · 2023: $17K · 2024: $20K · 2025: $6,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Honoraria: $12K · Food and Beverage: $8,376 · Travel and Lodging: $3,524 · Education: $53.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,000.00 |
| Honoraria | $11,900.00 |
| Food and Beverage | $8,376.06 |
| Travel and Lodging | $3,524.45 |
| Education | $53.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $43,894.90 | 2019-2025 | Veltassa |
| Amgen INC. | $24,187.21 | 2019-2025 | Krystexxa, Tavneos |
| Horizon Therapeutics Plc | $21,081.06 | 2019-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $11,466.77 | 2021-2025 | |
| Bard Peripheral Vascular, INC. | $2,478.54 | 2019-2024 | Covera, Lutonix Drug Coated Balloon, Fluency Endovascular Stent Graft |
| Astrazeneca Pharmaceuticals LP | $1,339.02 | 2019-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $439.43 | 2020-2025 | Acthar, Terlivaz |
| Aurinia Pharma U.S., INC. | $406.45 | 2021-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $349.77 | 2023-2025 | |
| Ardelyx, INC. | $323.56 | 2024-2025 | Ibsrela |
| Travere Therapeutics, INC. | $305.63 | 2022-2025 | |
| Sobi, INC | $280.95 | 2025 | |
| Opko Pharmaceuticals, LLC | $194.55 | 2019-2025 | Rayaldee |
| Mallinckrodt Enterprises LLC | $186.53 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $183.16 | 2019-2025 | Jynarque |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $159.88 | 2021-2023 | Venaseal, Chameleon |
| Lilly USA, LLC | $151.64 | 2023-2025 | Jardiance |
| Philips North America LLC | $143.95 | 2022-2024 | (Ak6) Vest Therapy |
| Renalytix Ai, INC. | $141.65 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Calliditas Therapeutics US INC. | $106.99 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $103.29 | 2019-2021 | |
| Chiesi USA, INC. | $94.93 | 2021-2023 | Kengreal, Cleviprex |
| Novo Nordisk INC | $86.48 | 2024-2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $83.00 | 2021-2023 | Injectafer |
| Becton, Dickinson and Company | $77.44 | 2024-2025 | Venclose Maven Catheter, Covera |
| Glaxosmithkline, LLC. | $76.35 | 2023 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.83 | 2023-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $58.40 | 2025 | Purified Cortrophin Gel |
| Abbvie INC. | $46.44 | 2025 | |
| Fresenius USA Marketing, INC. | $41.72 | 2019-2021 | |
| Genzyme Corporation | $37.29 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $36.80 | 2025 | Ultomiris |
| Abbott Laboratories | $36.74 | 2022-2023 | Eterna |
| Apellis Pharmaceuticals, INC. | $32.24 | 2025 | |
| Shield Therapeutics INC | $30.42 | 2025 | |
| Averitas Pharma INC. | $28.81 | 2025 | Qutenza |
| Argon Medical Devices, INC. | $23.51 | 2024 | Clot Management |
| Ascendis Pharma Endocrinology INC | $23.35 | 2025 | Yorvipath |
| Shire North American Group INC | $22.46 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $21.60 | 2022 | |
| Cormedix INC. | $19.44 | 2025 | Defencath |
| Takeda Pharmaceuticals U.S.A., INC. | $18.98 | 2022 | |
| Cmp Pharma, INC. | $18.70 | 2021 | |
| Scpharmaceuticals INC. | $16.20 | 2024 | |
| Mozarc Medical US LLC | $15.60 | 2023 | Chameleon |
| Arbor Pharmaceuticals, INC. | $12.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Saranathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.